** Shares of biopharmaceutical group HUTCHMED (China) Ltd 0013.HK jump 9.7% to HK$26, their highest since April 2
** Stock on course for third consecutive session of gains
** HUTCHMED and Іnnovent Biologics 1801.HK say in a joint statement that China National Medical Products Administration (NMPA) has accepted for review the New Drug Application for the combination of fruquintinib and sintilimab for treatment of renal cell carcinoma in kidney cancer
** Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly LLY.N
** Sintilimab is co-developed and co-commercialized by Іnnovent and Eli Lilly
** Hong Kong's healthcare index .HSCIH falls 1.6%, Hang Seng Biotech Index .HSHKBIO drops 1.8%
** YTD, HUTCHMEd stock up 5.8%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.